Minimizing your patients’ risks for cardiovascular morbidity and mortality
Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost every other dialysis patient dies from cardiovascular complications. Fresenius Medical Care supports nephrologists worldwide in minimizing their patients’ risks for cardiovascular morbidity and mortality.
HighVolumeHDF therapy as well as innovative membranes like Helixoneplus and modern monitoring features like the Blood Volume Monitor, together with ultrapure dialysis fluid, help minimize CVD risk factors and significantly improve the quality and efficacy of hemodialysis therapy.
Fresenius Medical Care strives continuously to develop and implement innovative therapies and products to improve the cardiovascular prognosis of dialysis patients.
Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details.